Table 2.
Characteristics of relapsed CML patients after allo-SCT based on BCR-ABL transcript pattern
| Persistently Negative (N= 26) | Persistently Positive (N= 33) | P value | ||
|---|---|---|---|---|
| n, (%) | n, (%) | |||
| Disease status | AP | 5 ( 19%) | 13 (39%) | 0.15 |
| CP | 21 (81%) | 20 (61%) | ||
| Pre-transplant TKI use | Yes | 3 (12%) | 9 (27%) | 0.20 |
| No | 23 (88%) | 24 (73%) | ||
| Post relapse TKI | Yes | 17 (65%) | 17 (52%) | 0.30 |
| No | 9 (35%) | 16 (48%) | ||
| Graft source | BM | 5 (19%) | 4 (12%) | 0.49 |
| PBSC | 21 (81%) | 29 (88%) | ||
| aGVHD grade II-IV | Yes | 9 (35%) | 8 (24%) | 0.40 |
| No | 17 (65%) | 25 (76%) | ||
| cGVHD grade | Extensive | 11 (42%) | 11 (33%) | 0.22 |
| Limited | 8 (31%) | 6 (18%) | ||
| No | 7 (27%) | 16 (49%) | ||
| IST>3years | Yes | 9 (35%) | 5 (15%) | 0.13 |
| No | 17 (65%) | 26 (85%) | ||
| Relapse type | Hematological | 1 (4%) | 21 (64%) | <0.001 |
| Molecular | 25 (96%) | 12 (36%) | ||
| Outcome | Death | 1 (4%) (1-AP) | 19 (58%) (12- AP; 7 CP) | <0.0001 |
| Alive | 25 (96%) | 14(42%) | ||
| Cause of death | Relapse | 0 (0%) | 16 (84%) (11-AP; 5CP) | 0.051 |
| Infection | 1 (100%) | 2 (11%) (2-CP) | ||
| Respiratory failure | 0 (0%) | 1 (5%) (1-AP) | ||
| Median post relapse survival | 3060 days | 814 days | <0.0001 (log-rank test) | |
Abbreviations: AP: Advanced phase; CP: Chronic phase; BM: bone marrow; PBSC, peripheral blood stem cell; aGVHD: acute graft versus host disease; cGVHD: chronic graft versus host disease; IST, immunosuppressive therapy; TKI: tyrosine kinase inhibitor